Perspective Therapeutics (CATX) vs Owlet (OWLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Owlet (OWLT) over the past year, losing 31.1% versus a loss of 47.4%. Over five years, CATX leads with a -57.1% price change compared with -91.2% for OWLT. Perspective Therapeutics is the larger company by market cap ($303.6 million vs $138.2 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | OWLT |
|---|---|---|
| Share price | $2.66 | $4.73 |
| Market cap | $303.64M | $138.22M |
| 1-day change | -1.85% | +1.50% |
| YTD return | -3.27% | -70.78% |
| 1-year return | -31.09% | -47.44% |
| 5-year return | -57.10% | -91.22% |
| Forward P/E | — | 21.50 |
| EPS (TTM) | $-1.33 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $16.94 |
| 52-week low | $1.96 | $4.19 |
| Distance from 52-week high | -56.82% | -72.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +362.03% | +174.84% |
| Average volume | 1.64M | 190.76K |
| Shares outstanding | 114.15M | 29.22M |
| Employees | 163 | 108 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Perspective Therapeutics is about 2.2 times larger than Owlet by market value ($303.64M vs $138.22M).
- CATX has outperformed OWLT by 16.4 percentage points over the past year.
- The two companies sit in different sectors: Perspective Therapeutics in Health Care and Owlet in Industrials.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Owlet
OWLT stock →Owlet, Inc. provides digital parenting solutions in the United States, the United Kingdom, and internationally.
Industrials · Industrial Machinery/Components · 108 employees
CATX vs OWLT FAQ
Which is bigger, Perspective Therapeutics or Owlet?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $303.64M compared with $138.22M for Owlet (OWLT).
Which stock has performed better over the past year, CATX or OWLT?
CATX returned -31.09% over the past 12 months, compared with -47.44% for OWLT (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Owlet in the same industry?
No. Perspective Therapeutics is in the Health Care sector, while Owlet is in Industrials.